"Before engaging in off-label promotion, companies should ascertain the risk profile, safety, efficacy, and potential commercial benefits of the use -- without committing that last bit to print".

Indeed, Allergan claims the regulations violate the right to free speech under the First ... “the charge was not directly related to the off-label promotion but to a press release that ...